As the autoimmune drug development landscape evolved, the promise of T-cell engagers (TCEs) was becoming impossible to ignore. Unlike cell therapies, TCEs offer a more cost-effective, off-the-shelf option with easier administration and reduced logistical hurdles making them ideal for treating chronic autoimmune diseases.

In 2025, what began in oncology was then being smartly re-engineered for autoimmunity: optimized CD3 affinities, new strategies to mitigate CRS, and highly selective targeting were paving the way for safer, more durable TCE therapies. But unlocking the full potential of TCEs for autoimmune conditions demanded focused, cross-functional collaboration.

That’s where the T-Cell Engager for Autoimmune Disease Summit came in. This was the only industry meeting solely dedicated to TCEs in autoimmunity bringing together translational scientists, immunology pioneers, and drug development leaders to tackle the specific preclinical, mechanistic, and regulatory hurdles unique to this modality.

Whether you were developing novel formats, exploring new immune targets, or preparing for IND submission, this summit provided the deep technical exchange and curated networking you needed to move forward with confidence.